Genprex, Inc. 8-K

What Happened

• Genprex, Inc. announced on January 7, 2026 that Nasdaq's Hearings Panel determined the company has regained compliance with the $2.5 million minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The determination follows a previously disclosed Nasdaq notice dated August 19, 2025 that indicated the company was then out of compliance.
• Nasdaq will require a mandatory panel monitor for Genprex through January 7, 2027 pursuant to Listing Rule 5815(d)(4)(B). If Nasdaq’s Listing Qualifications Staff finds Genprex out of compliance again during that one-year monitoring period, Nasdaq will not permit the company to submit a plan or be granted additional cure time for that same deficiency; instead, the Staff would issue a Delist Determination Letter and the company could seek a hearing, with potential delisting of its securities.

Key Details

• Date of Compliance Notice: January 7, 2026.
• Minimum required stockholders’ equity: $2.5 million (Nasdaq Listing Rule 5550(b)(1)).
• Monitoring period: mandatory panel monitor through January 7, 2027 (Listing Rule 5815(d)(4)(B)).
• Prior related notice: Nasdaq letter to Genprex dated August 19, 2025 indicating noncompliance.

Why It Matters

• Regaining compliance removes the immediate threat of delisting tied to the previously noted equity deficiency, preserving Genprex’s Nasdaq listing for now.
• However, the one-year mandatory monitoring heightens regulatory scrutiny: a repeat deficiency during the monitor period would trigger a faster delisting process without the usual opportunity for additional cure time or a compliance plan.
• Investors should track Genprex’s upcoming filings and any further Nasdaq communications, since future noncompliance during the monitoring period could materially affect the company’s listing status and stock liquidity.